Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cullinan Therapeutics, Inc.CGEM · Entity 4766 | Chief Medical Officer | January 07, 2021 | January 11, 2021 |
| MACROGENICS INCMGNX · Entity 6104 | Sr VP, Clinical Dev. & CMO | February 20, 2020 | February 24, 2020 |
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | Director | June 05, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cullinan Therapeutics, Inc.
Report date January 07, 2021 · Filed January 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.00 · Expires 2031-01-06 | Direct | 116,666 |
Reported balance
After 2021-01-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-07 · Grant · Acquired 116,666 · Balance 116,666 F1: The option represents a right to purchase a total of 116,666 shares of the Issuer's Common Stock, 25% of which will become fully vested and exercisable on January 7, 2022, with the remaining shares vesting in equal monthly installments over the following three years (36 months), subject to the reporting person's continued employment with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option represents a right to purchase a total of 116,666 shares of the Issuer's Common Stock, 25% of which will become fully vested and exercisable on January 7, 2022, with the remaining shares vesting in equal monthly installments over the following three years (36 months), subject to the reporting person's continued employment with the Issuer.
MACROGENICS INC
Report date February 20, 2020 · Filed February 24, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2030-02-20 | Direct | 100,000 |
Reported balance
After 2020-02-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-20 · Grant · Acquired 100,000 · Balance 100,000 F1: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter.
SUTRO BIOPHARMA, INC.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.09 · Expires 2036-06-05 | Direct | 10,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 10,000 · Balance 10,000 F1: The option shall vest, subject to the reporting person's provision of service to the issuer on each vesting date, as to 8.33% of the total award monthly, with the first tranche vesting on July 5, 2026, and the award shall be fully vested and exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 5, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest, subject to the reporting person's provision of service to the issuer on each vesting date, as to 8.33% of the total award monthly, with the first tranche vesting on July 5, 2026, and the award shall be fully vested and exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 5, 2027.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Checkmate Pharmaceuticals, Inc.
Report date May 31, 2022 · Filed May 31, 2022
Section 16 reporting ended · disclosed 2022-05-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.19 · Expires 2032-01-29 | Direct | 0 |
Reported balance
After 2022-05-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-31 · Disposition to issuer · Disposed 20,061 · Balance 0 F1: At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the "Issuer"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the "Merger"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an "In the Money Issuer Option") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the "Issuer"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the "Merger"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an "In the Money Issuer Option") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 9, 2026 20:24 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $26.09 | $0.00 |
DisclosureSEC source: 0001587487-26-000002 · form4-06092026_080649.xml · derivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-06-05 F1 · derivative.exercise_date: The option shall vest, subject to the reporting person's provision of service to the issuer on each vesting date, as to 8.33% of the total award monthly, with the first tranche vesting on July 5, 2026, and the award shall be fully vested and exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 5, 2027. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 22:05 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001587487-25-000004 · form4-12292025_101249.xml · derivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2035-12-23 F1 · derivative.exercise_date: The option shall vest as to 16.67% of the total award monthly, subject to the reporting person's continued service to the issuer on each vesting date, with the first tranche vesting on January 23, 2026. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:14 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001415889-25-016471 · form4-06102025_080610.xml · derivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-06-06 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 6, 2025, with 100% of the total shares vested and exercisable on the earlier of the date of the issuer's 2026 annual stockholders meeting or June 6, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:31 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001415889-24-016228 · form4-06102024_080603.xml · derivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-06-06 F1 · derivative.exercise_date: The option vests as to 8.33% of the total award monthly, commencing July 6, 2024, with 100% of the award vested and exercisable on the earlier of the date of the issuer's 2025 annual stockholders meeting or June 6, 2025, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 22:40 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.12 | $0.00 |
DisclosureSEC source: 0001209191-23-036474 · doc4.xml · derivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 8, 2023, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2024 annual stockholders meeting or June 8, 2024, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:11 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 18,500 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001209191-22-035213 · doc4.xml · derivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2032-06-05 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 6, 2022, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2023 annual stockholders meeting or June 6, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| May 31, 2022 Filed May 31, 2022 10:02 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,061 | Not disclosed Strike: $2.19 | Not disclosed |
DisclosureSEC source: 0000899243-22-020079 · doc4.xml · derivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,061 shares Expires 2032-01-29 F1 · kind: At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the "Issuer"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the "Merger"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an "In the Money Issuer Option") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes. F1 · price: At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the "Issuer"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the "Merger"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an "In the Money Issuer Option") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes. F1 · derivative.exercise_date: At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the "Issuer"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the "Merger"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an "In the Money Issuer Option") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes. Read SEC document |
| January 30, 2022 Filed Feb 1, 2022 16:25 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | GrantStock Option (Right to Buy) · Derivative | 20,061 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0000899243-22-003865 · doc4.xml · derivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,061 Underlying: Common Stock · 20,061 shares Expires 2032-01-29 F1 · derivative.exercise_date: This stock option shall vest 1/3 on the first anniversary of the grant date and monthly thereafter through the third anniversary of the grant date, subject to the Reporting Persons continued service through such date. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 21:08 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 18,500 | $0.00 Strike: $18.21 | $0.00 |
DisclosureSEC source: 0001209191-21-038701 · doc4.xml · derivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2031-06-02 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 3, 2021, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2022 annual stockholders meeting or June 3, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 17:32 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 116,666 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0000899243-21-001360 · doc4.xml · derivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,666 Underlying: Common Stock · 116,666 shares Expires 2031-01-06 F1 · derivative.exercise_date: The option represents a right to purchase a total of 116,666 shares of the Issuer's Common Stock, 25% of which will become fully vested and exercisable on January 7, 2022, with the remaining shares vesting in equal monthly installments over the following three years (36 months), subject to the reporting person's continued employment with the Issuer. Read SEC document |
| November 30, 2020 Filed Dec 1, 2020 22:10 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $17.10 | $0.00 |
DisclosureSEC source: 0001209191-20-060914 · doc4.xml · derivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-11-29 F1 · derivative.exercise_date: The option vests as to 2.778% of the total shares monthly, beginning on December 30, 2020, with 100% of the total shares vested and exercisable on November 30, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 21:46 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 100,000 | $11.50 Strike: $11.50 | $1,150,000.00 |
DisclosureSEC source: 0001125345-20-000024 · wf-form4_158258077603500.xml · derivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-02-20 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 21:02 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 90,000 | $0.00 Strike: $21.88 | $0.00 |
DisclosureSEC source: 0001125345-19-000031 · wf-form4_155112852052571.xml · derivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-02-21 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 22:23 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 70,000 | $0.00 Strike: $28.94 | $0.00 |
DisclosureSEC source: 0001125345-18-000043 · wf-form4_152037501659395.xml · derivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-03-02 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 22:49 UTC | MACROGENICS INC MGNX · Entity 6104 | Tax withholdingCommon Stock | 11,070 | $23.46 | $259,702.20 |
DisclosureSEC source: 0001125345-18-000027 · wf-form4_151977175494111.xml · nonDerivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,930 F1 · shares: Represents shares of common stock withheld to pay taxes upon vesting of restricted stock units originally granted to the Reporting Person on 2/25/16. The number of shares withheld was determined on 2/26/18 based on the closing price of Company common stock on that day. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 22:19 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 2,524 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001125345-18-000007 · wf-form4_151631396295775.xml · derivative · entry 6 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,448 Underlying: Common Stock · 2,524 shares Expires 2023-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 22:19 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 2,524 | $20.00 | $50,480.00 |
DisclosureSEC source: 0001125345-18-000007 · wf-form4_151631396295775.xml · nonDerivative · entry 4 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F2 · date: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $20 to $20.03. F1 · balance_after: This amount includes 30,000 Restricted Stock Units (RSU) acquired on 2/25/16 which will vest on 2/25/18. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 22:19 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 2,524 | $4.70 | $11,862.80 |
DisclosureSEC source: 0001125345-18-000007 · wf-form4_151631396295775.xml · nonDerivative · entry 3 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This amount includes 30,000 Restricted Stock Units (RSU) acquired on 2/25/16 which will vest on 2/25/18. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 22:19 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 2,476 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001125345-18-000007 · wf-form4_151631396295775.xml · derivative · entry 5 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,972 Underlying: Common Stock · 2,476 shares Expires 2023-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 22:19 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 2,476 | $20.00 | $49,520.00 |
DisclosureSEC source: 0001125345-18-000007 · wf-form4_151631396295775.xml · nonDerivative · entry 2 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F2 · date: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $20 to $20.71. F1 · balance_after: This amount includes 30,000 Restricted Stock Units (RSU) acquired on 2/25/16 which will vest on 2/25/18. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 22:19 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 2,476 | $4.70 | $11,637.20 |
DisclosureSEC source: 0001125345-18-000007 · wf-form4_151631396295775.xml · nonDerivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This amount includes 30,000 Restricted Stock Units (RSU) acquired on 2/25/16 which will vest on 2/25/18. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 22:15 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 5,000 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001125345-17-000116 · wf-form4_151130253889619.xml · derivative · entry 3 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,448 Underlying: Common Stock · 5,000 shares Expires 2023-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 22:15 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 5,000 | $20.00 | $100,000.00 |
DisclosureSEC source: 0001125345-17-000116 · wf-form4_151130253889619.xml · nonDerivative · entry 2 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · date: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $20 to $20.03 F3 · balance_after: This amount includes 30,000 Restricted Stock Units (RSU) acquired on 2/25/16 which will vest on 2/25/18. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 22:15 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 5,000 | $4.70 | $23,500.00 |
DisclosureSEC source: 0001125345-17-000116 · wf-form4_151130253889619.xml · nonDerivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 25, 2017 Filed Oct 26, 2017 13:37 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 10,000 | $4.70 Strike: $4.70 | $47,000.00 |
DisclosureSEC source: 0001125345-17-000099 · wf-form4_150902503619614.xml · derivative · entry 3 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,448 Underlying: Common Stock · 10,000 shares Expires 2023-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 25, 2017 Filed Oct 26, 2017 13:37 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 10,000 | $20.00 | $200,000.00 |
DisclosureSEC source: 0001125345-17-000099 · wf-form4_150902503619614.xml · nonDerivative · entry 2 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · date: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017 F2 · price: This transaction was executed in multiple trades at prices ranging from $20 to $20.145. F3 · balance_after: This amount includes 30,000 Restricted Stock Units (RSU) acquired on 2/25/16 which will vest on 2/25/18. Read SEC document |
| October 25, 2017 Filed Oct 26, 2017 13:37 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 10,000 | $4.70 | $47,000.00 |
DisclosureSEC source: 0001125345-17-000099 · wf-form4_150902503619614.xml · nonDerivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2017 Filed Jun 6, 2017 20:04 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 5,000 | $4.70 Strike: $4.70 | $23,500.00 |
DisclosureSEC source: 0001125345-17-000083 · wf-form4_149677942918537.xml · derivative · entry 3 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,448 Underlying: Common Stock · 5,000 shares Expires 2023-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2017 Filed Jun 6, 2017 20:04 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 5,000 | $20.00 | $100,000.00 |
DisclosureSEC source: 0001125345-17-000083 · wf-form4_149677942918537.xml · nonDerivative · entry 2 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · date: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2016. F2 · price: This transaction was executed in multiple trades at prices ranging from $20 to $20.02. F3 · balance_after: This amount includes 30,000 Restricted Stock Units (RSU) acquired on 2/25/16 which will vest on 2/25/18. Read SEC document |
| June 05, 2017 Filed Jun 6, 2017 20:04 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 5,000 | $4.70 | $23,500.00 |
DisclosureSEC source: 0001125345-17-000083 · wf-form4_149677942918537.xml · nonDerivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2017 Filed Apr 20, 2017 20:15 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001125345-17-000044 · wf-form4_149271930447577.xml · derivative · entry 3 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,448 Underlying: Common Stock · 15,000 shares Expires 2023-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2017 Filed Apr 20, 2017 20:15 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 15,000 | $20.00 | $300,000.00 |
DisclosureSEC source: 0001125345-17-000044 · wf-form4_149271930447577.xml · nonDerivative · entry 2 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · date: The sales reported in this form 4 were effected pursuant to a Rule 10b-5 trading plan adopted by the reporting person on December 15, 2016. F2 · price: This transaction was executed in multiple trades at prices ranging from $20 to $20.03. F3 · balance_after: This amount includes 30,000 Restricted Stock Units (RSU) acquired on 2/25/16 which vest on 2/25/18. Read SEC document |
| April 19, 2017 Filed Apr 20, 2017 20:15 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 15,000 | $4.70 | $70,500.00 |
DisclosureSEC source: 0001125345-17-000044 · wf-form4_149271930447577.xml · nonDerivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 22:44 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantCommon Stock · Derivative | 67,500 | $20.53 Strike: $20.53 | $1,385,775.00 |
DisclosureSEC source: 0001125345-17-000029 · wf-form4_148728505201545.xml · derivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2027-02-15 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 20:49 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001552781-16-001977 · e00529_wigginton-form4.xml · derivative · entry 3 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,254 Underlying: Common Stock · 10,000 shares Expires 2023-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 20:49 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 10,000 | $29.34 | $293,400.00 |
DisclosureSEC source: 0001552781-16-001977 · e00529_wigginton-form4.xml · nonDerivative · entry 2 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2016. F2 · price: This transaction was executed in multiple trades at prices ranging from $28.755 to $29.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 20:49 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 10,000 | $4.70 | $47,000.00 |
DisclosureSEC source: 0001552781-16-001977 · e00529_wigginton-form4.xml · nonDerivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2016. Read SEC document |
| October 03, 2016 Filed Oct 19, 2016 21:20 UTC Amendment | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001552781-16-002003 · e00451_wigginton-form4a.xml · derivative · entry 3 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,254 Underlying: Common Stock · 10,000 shares Expires 2023-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: Due to a clerical error, the reporting person is filing this amendment to the Form 4 originally filed on October 5, 2016 to correct the number of derivative securities beneficially owned following the reported transaction from 15,254 to 25,254. Read SEC document |
| October 03, 2016 Filed Oct 19, 2016 21:20 UTC Amendment | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 10,000 | $29.34 | $293,400.00 |
DisclosureSEC source: 0001552781-16-002003 · e00451_wigginton-form4a.xml · nonDerivative · entry 2 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2016. F2 · price: This transaction was executed in multiple trades at prices ranging from $28.755 to $29.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 03, 2016 Filed Oct 19, 2016 21:20 UTC Amendment | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 10,000 | $4.70 | $47,000.00 |
DisclosureSEC source: 0001552781-16-002003 · e00451_wigginton-form4a.xml · nonDerivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2016. Read SEC document |
| October 03, 2016 Filed Feb 8, 2017 22:27 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 10,000 | $29.34 | $293,400.00 |
DisclosureSEC source: 0001125345-17-000020 · wf-form5_148659286027412.xml · nonDerivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · balance_after: Due to clerical error, the amount of securities beneficially owned after the transaction on 10/3/16 and reported on a Form 4 on 10/19/16, was incorrect. The corrected amount includes 30,000 Restricted Stock Units (RSU) acquired on 2/25/16 which vest on 2/25/18. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.